Antisense And Rnai Therapeutics Market Size, Share, Growth, 2034


Date:

(MENAFN- Straits Research) Antisense and RNAi Therapeutics Market Size, Share & Growth Analysis

The global antisense and rnai therapeutics market size was valued at USD 4.69 billion in 2025 and is projected to grow from USD 5.51 billion in 2026 to USD 19.93 billion by 2034, registering a CAGR of 17.44%. North America dominated the antisense and rnai therapeutics market with a share of 42.3% in 2025.

Antisense and rnai therapeutics are advanced genetic medicines designed to regulate or reduce the production of specific proteins by targeting messenger RNA (mRNA). Antisense therapies use short synthetic nucleic acid sequences, while RNA interference (RNAi) therapies use small RNA molecules to silence specific genes. These treatments are being developed for genetic disorders, neurological conditions, cancers, and other diseases. Antisense and RNAi Therapeutics Market Key TakeawaysGlobal Market Size & Growth2025 Market Size USD 4.69 billion2026 Market Size USD 5.51 billion2034 Projected Market Size USD 19.93 billionForecast Period 2026–2034Base Year 2025Market CAGR (2026–2034) 17.44%Regional Insights Largest Regional Market (2025) North America North America Market Share (2025) 42.3% Fastest-growing Region Europe Europe CAGR (2026–2034) 20.4%Segment Insights By Technology Leading Segment RNA Interference Market Share in 2025 29.4% By Application Fastest-growing Segment Genetic Disorders CAGR (2026–2034) 22.1% By Route of Administration Leading Segment Subcutaneous Route Market Share in 2025 31.2%

Download a Free Sample To learn more about this report.

01

Extrahepatic RNA Delivery Technologies

The antisense and rnai therapeutics market analysis highlights how the need to treat diseases beyond the liver is encouraging the development of extrahepatic RNA delivery technologies. The transition toward targeted lipid nanoparticle, peptides, and ligand-based carriers helps deliver RNA molecules to tissues such as the lungs, muscles, and central nervous system. For example, researchers are exploring inhaled lipid nanoparticles to deliver RNA therapeutics directly to lung tissue.

02

GalNAc-Conjugated RNA Therapeutics

The need for efficient and targeted liver delivery is supporting the adoption of GalNAc-conjugated RNA therapeutics. The transition toward GalNAc-siRNA conjugates improves uptake by liver cells through their asialoglycoprotein receptors. For example, Amgen's olpasiran and Alnylam's inclisiran demonstrate the clinical use of targeted RNA-based approaches for cardiovascular conditions.

Antisense and RNAi Therapeutics Market Dynamics 01

Prevalence of Genetic and Rare Diseases Drive Market

Genetic conditions such as spinal muscular atrophy, hereditary transthyretin amyloidosis, and certain inherited neurological disorders create requirements for targeted treatment options. These medical needs support clinical research and procurement of antisense and RNAi therapeutics by specialty healthcare providers. For example, nusinersen (Spinraza) is an antisense medicine used to treat spinal muscular atrophy, supporting the use of RNA-targeting therapies in rare disease care.

02

Limitations of Conventional Drug Therapies Market Demand

Conventional medicines often provide limited treatment options for diseases caused by specific genetic mutations or abnormal RNA activity. These treatment gaps encourage pharmaceutical companies to develop antisense and RNAi therapies that target disease-related RNA, supporting research investment and clinical adoption. For example, patisiran (Onpattro) uses RNA interference to reduce transthyretin protein production in patients with hereditary transthyretin amyloidosis.

03

Impact Analysis of Key Drivers in Antisense and RNAi Therapeutics Market

DriversMarket Impact
Prevalence of Genetic and Rare Diseases Genetic disorders create requirements for targeted treatment options, supporting research, clinical development, and commercial adoption of antisense and RNAi medicines.
Limitations of Conventional Drug Therapies Inadequate treatment options for certain conditions encourage pharmaceutical companies to invest in gene-targeting therapies, supporting product development and clinical research activity.
Expansion of Precision Medicine Programs Personalized treatment approaches support the use of genetic testing and targeted therapeutics, creating opportunities for antisense and RNAi drug developers.
Pharmaceutical Investment in RNA-Based Drug Development Research funding and strategic partnerships support clinical trials, manufacturing capacity, and commercialization activities for RNA-targeting medicines.
Clinical Trial Activity for Neurological and Metabolic Disorders Clinical research into conditions such as spinal muscular atrophy, amyloidosis, and metabolic disorders supports development pipelines and future treatment availability.
Regulatory Support for Innovative Genetic Medicines Regulatory pathways for specialized therapies help eligible drug candidates progress through clinical evaluation and approval, supporting market entry and commercialization.
01

Challenges in Delivering Therapeutics to Target Cells Restrain Market Expansion

Antisense and RNAi molecules can face barriers such as enzymatic degradation, poor cellular uptake, and limited tissue penetration before reaching their intended targets. Delivery systems such as lipid nanoparticles and chemical modifications help address these issues but may not provide effective distribution across all tissues. These limitations can reduce treatment effectiveness and restrict the development of therapies for diseases beyond the liver.

02

Risk of Off-Target Gene Silencing

Unintended interactions between therapeutic molecules and non-target RNA sequences can affect genes that are not involved in the intended treatment. Such interactions may trigger unwanted biological effects and complicate the evaluation of treatment safety. These concerns can increase clinical development requirements and limit the adoption of antisense and RNAi therapies across a wider range of diseases.

03

Impact Analysis of Key Restraints in Antisense and RNAi Therapeutics Market

RestraintsMarket Impact
Challenges in Delivering Therapeutics to Target Cells Antisense and RNAi molecules can face barriers such as rapid degradation and limited cellular uptake, making it difficult to reach the intended tissues at effective concentrations. These delivery limitations can restrict therapeutic effectiveness and slow the development of new treatments.
Risk of Off-Target Gene Silencing Unintended interactions with non-target RNA sequences can affect genes beyond the intended target and lead to unwanted biological effects. These concerns can increase development complexity and limit the clinical application of antisense and RNAi therapies.
Limited Long-Term Safety Data The effects of repeated dosing and prolonged gene-expression modulation may require extended clinical evaluation. Gaps in long-term safety evidence can make healthcare providers cautious and slow the adoption of these therapies.
Complexity of Clinical Trial Design Rare genetic conditions, small patient populations, and disease-specific endpoints can make it difficult to recruit participants and measure treatment outcomes. These challenges can extend clinical development timelines and delay the availability of new therapies.
High Biological Variability in Treatment Response Differences in genetic profiles, disease progression, and target-gene expression can cause patients to respond differently to the same therapy. This variability can complicate dose selection and limit consistent treatment outcomes across patient groups.
01

Clinical Trial Support Services Offers Growth Opportunities

Biotechnology companies, pharmaceutical developers, and research institutions benefit from clinical trial support services that help evaluate the safety and effectiveness of antisense and RNAi therapies. Clinical research management, patient recruitment, laboratory testing, and regulatory support create revenue opportunities for providers such as IQVIA, ICON plc, and Parexel.

02

Oligonucleotide Quality Testing

Pharmaceutical manufacturers, biotechnology firms, and contract development organizations benefit from specialized quality testing that verifies the purity, identity, potency, and stability of oligonucleotide-based therapeutics. Analytical testing, batch release services, stability studies, and quality control contracts create revenue avenues for companies such as Eurofins Scientific, Charles River Laboratories, and Thermo Fisher Scientific, supporting antisense and rnai therapeutics market growth.

Antisense and RNAi Therapeutics Market Segmentation Analysis By Technology

RNA interference maintained a prominent position in the technology segment, accounting for a share of 29.4% in 2025. This dominance is supported by its ability to regulate gene expression by targeting specific RNA molecules. Its applications across therapeutic research and the development of treatments for genetic and chronic diseases continue to support its market presence.

siRNA is witnessing broader adoption, registering a CAGR of 21.2% during the forecast period. Its ability to selectively silence disease-associated genes supports the development of targeted therapies. Advances in delivery technologies and clinical research are further supporting its adoption across RNA-based treatments.

Request Customization to receive a tailored report.

By Application

Oncology held a prominent position in the application segment, accounting for a share of 26.8% in 2025. This dominance is supported by the potential of RNA-based therapeutics to target cancer-related genes and regulate abnormal protein expression. Their applications in targeted cancer treatment and therapeutic research continue to support the segment's market presence.

Genetic disorders are witnessing faster growth, registering a CAGR of 22.1% during the forecast period. The ability of RNA therapeutics to modify gene expression and address disease-causing genetic abnormalities supports their development for inherited conditions. Advancements in precision medicine and targeted RNA delivery further encourage research in this application.

By Route of Administration

Subcutaneous route maintained a leading position in the route of administration segment, accounting for a share of 31.2% in 2025. This preference is supported by its convenience, suitability for repeated dosing, and potential for self-administration. Its use in delivering RNA-based medicines across different therapeutic areas continues to support its market presence.

Intrathecal route is witnessing faster adoption, registering a CAGR of 21.5% during the forecast period. Direct administration into cerebrospinal fluid enables RNA therapeutics to reach the central nervous system. This delivery approach supports the development of treatments for neurodegenerative and other neurological disorders.

Speak to an Analyst to discuss market opportunities.

Antisense and RNAi Therapeutics Market Regional OutlookNorth America Antisense and RNAi Therapeutics Market

The North America antisense and rnai therapeutics market accounted for the dominant share of 42.3% in 2025.

United States Antisense and RNAi Therapeutics Market

The fda updated the label for olezarsen (Tryngolza), an antisense oligonucleotide, in June 2026 to include treatment of severe hypertriglyceridemia, widening its approved therapeutic use. Dyne Therapeutics also initiated its Phase III HARMONIA trial in 2026, targeting approximately 150 participants with myotonic dystrophy type 1, supporting further clinical development of ASO-based therapies.

Canada Antisense and RNAi Therapeutics Market

The Canadian Institutes of Health Research lists a CAD 1.1475 million, five-year project grant for developing an antisense oligonucleotide therapy targeting DUX4 in facioscapulohumeral muscular dystrophy. The project focuses on delivery optimisation and safety testing, creating a potential pathway toward clinical development and future commercialisation.

Unlock Regional Insights to access country-level data, & regional trends.

Europe Antisense and RNAi Therapeutics Market

The Europe antisense and rnai therapeutics market is expected to grow at a CAGR of 20.4% during the forecast period, showcasing the fastest-growing regional market.

U.K. Antisense and RNAi Therapeutics Market

The UK Government awarded Innovation Passports in 2026 to an investigational siRNA therapy for Huntington's disease and an antisense oligonucleotide for early Alzheimer's disease under its Innovative Licensing and Access Pathway. This regulatory support can help promising RNA-targeting treatments progress through development and access planning, although an Innovation Passport is not a marketing authorisation.

Germany Antisense and RNAi Therapeutics Market Germany recorded two recruiting Phase II studies in 2026 involving aganirsen-related antisense eye-drop research at the University of Cologne, including programmes for corneal neovascularisation. These studies indicate continued investigation of local oligonucleotide delivery and may support future development of specialised antisense treatments Pacific Antisense and RNAi Therapeutics Market

The Asia Pacific antisense and rnai therapeutics market accounted for a regional share of 21.2% in 2025.

Japan Antisense and RNAi Therapeutics Market

A first-in-Japanese Phase I study of sefaxersen, an antisense oligonucleotide targeting complement factor B, reported that all 24 participants completed the trial in 2026, with no new safety signals. Japan also registered the Phase III HARMONIA trial of DYNE-101 in April 2026, with an initial target of 12 participants, adding to its clinical pipeline for RNA-targeting treatments.

China Antisense and RNAi Therapeutics Market

Aligos Therapeutics and its Chinese partner Amoytop initiated a Phase I study of the antisense candidate ALG-170675 in August 2026 for chronic hepatitis B. Separately, China's NMPA cleared ART5, an investigational antisense therapy for autosomal dominant polycystic kidney disease, to begin first-in-human clinical testing, supporting the country's expanding oligonucleotide pipeline.

India Antisense and RNAi Therapeutics Market

An October 2026 industry update reported India's participation in clinical research for Duchenne muscular dystrophy exon-skipping therapies, including Phase II/III and Phase I antisense oligonucleotide programmes; recruitment was still pending for the cited studies. Separately, CSIR-IGIB's SCA12 research programme is developing an ASO approach targeting PPP2R2B, although it remains at an early research stage rather than human clinical testing

Competitive Landscape

The antisense and rnai therapeutics market is moderately consolidated, with pharmaceutical companies, biotechnology firms, RNA therapy developers, and specialized drug discovery companies competing in this space players such as GSK plc, Olix Pharmaceutical, Inc., Sanofi, Alnylam Pharmaceuticals, Inc., and Arbutus Biopharma are estimated to collectively account for 20–25% of the global antisense and rnai therapeutics market share.

Established players compete through clinical efficacy, delivery technologies, research capabilities, regulatory approvals, and commercialization partnerships, while the antisense and rnai therapeutics market ecosystem also includes emerging players that focus on innovative RNA platforms, targeted delivery systems, cost-effective therapies, and specialized gene-silencing applications.

List of Key and Emerging Players in Antisense and RNAi Therapeutics Market GSK plc (United Kingdom OliX Pharmaceuticals, Inc. (South Korea) Sanofi S.A. (France) Alnylam Pharmaceuticals, Inc. (U.S.) Arbutus Biopharma Corporation Canada Benitec Biopharma Inc. (Australia) Silence Therapeutics plc (United Kingdom) Ionis Pharmaceuticals, Inc. (U.S.) Sarepta Therapeutics, Inc. (U.S.) Percheron Therapeutics Limited (Australia)Key Industry Developments August 2026 Aligos Therapeutics announced that its partner Xiamen Amoytop Biotech had dosed the first participant in a Phase I study of ALG-170675, a next-generation antisense oligonucleotide for chronic hepatitis B. The candidate combines hepatitis B surface antigen RNA inhibition with immune activation to explore a potential functional cure. June 2026 Alnylam Pharmaceuticals and Regeneron Pharmaceuticals expanded their strategic collaboration to advance RNA interference (RNAi) therapeutics for cardiovascular and metabolic diseases, broadening their joint pipeline and strengthening long-term research and commercialization efforts. April 2026 Ionis Pharmaceuticals entered into a global licensing agreement with Sarepta Therapeutics to develop and commercialize next-generation antisense oligonucleotide (ASO) therapies for rare neuromuscular diseases, expanding the application of RNA-targeted therapeutics. January 2026 Wave Life Sciences announced the initiation of a strategic collaboration with GSK to develop RNA editing and oligonucleotide therapeutics for multiple genetic diseases, combining Wave's PRISM platform with GSK's global development capabilities ScopeSegmentation By Technology 4
    RNA Interference siRNA miRNA Antisense RNA
By Application 8
    Oncology Cardiovascular Diseases (CVDs) Respiratory Disorders Renal Diseases Neurodegenerative Disorders Genetic Disorders Infectious Diseases Others
By Route of Administration 6
    Intravenous Route Subcutaneous Route Intrathecal Route Pulmonary Delivery Intraperitoneal Injection Others
Geographies Covered North America 2
    U.S. Canada
Europe 8
    U.K. Germany France Spain Italy Russia Nordic Benelux
APAC 8
    China Korea Japan India Australia Singapore Taiwan South East Asia
Middle East and Africa 6
    UAE Turkey Saudi Arabia South Africa Egypt Nigeria
LATAM 5
    Brazil Mexico Argentina Chile Colombia
Competitive Coverage GSK plc (United Kingdom) · OliX Pharmaceuticals, Inc. (South Korea) · Sanofi S.A. (France) · Alnylam Pharmaceuticals, Inc. (U.S.) · Arbutus Biopharma Corporation Canada) Research Deliverables Revenue Forecast, Competitive Landscape, Growth Factors, Environment & Regulatory Landscape and Trends

Customize This Report to Match Your Strategic Objectives

Frequently Asked Questions (FAQs) The antisense and rnai therapeutics market size is valued at USD 5.51 Billion in 2026 and is projected to reach USD 19.93 Billion by 2034, at a CAGR of 17.44% during the forecast period 2026-2034. North America dominated the market with a share of 42.3% in 2025. The leading players in this market are GSK plc, Olix Pharmaceuticals, Inc., Sanofi, Alnylam Pharmaceuticals. The antisense and rnai therapeutics market is projected to grow at a CAGR of 17.44% during the forecast period of 2026 2034.

MENAFN16112026004597010906ID1111966720


Straits Research

Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.



More Story

Search